196861-33-3 Usage
Uses
Used in Organic Synthesis:
2-Methoxy-5-(pyridin-4-yl)phenylboronic acid is used as a reagent in Suzuki-Miyaura cross-coupling reactions for the formation of carbon-carbon bonds, which are crucial in constructing complex organic molecules.
Used in Pharmaceutical Development:
This boronic acid derivative is utilized in the development of pharmaceuticals, where its unique structure contributes to the design of new drug molecules with potential therapeutic applications.
Used in Agrochemical Production:
2-Methoxy-5-(pyridin-4-yl)phenylboronic acid is employed in the synthesis of agrochemicals, playing a role in the creation of compounds that can be used in agricultural applications to protect crops and enhance yields.
Used in Material and Fine Chemicals Production:
2-METHOXY-5-(PYRIDIN-4-YL)PHENYLBORONIC ACID is also used in the production of materials and fine chemicals, where its properties can be leveraged to create specialty products for various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 196861-33-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,6,8,6 and 1 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 196861-33:
(8*1)+(7*9)+(6*6)+(5*8)+(4*6)+(3*1)+(2*3)+(1*3)=183
183 % 10 = 3
So 196861-33-3 is a valid CAS Registry Number.
InChI:InChI=1/C12H12BNO3/c1-17-12-3-2-10(8-11(12)13(15)16)9-4-6-14-7-5-9/h2-8,15-16H,1H3
196861-33-3Relevant academic research and scientific papers
Manley, Paul W.,Acemoglu, Murat,Marterer, Wolfgang,Pachinger, Werner
, p. 436 - 445 (2003)
5-[2-Methoxy-5-(4-pyridinyl)phenyl]-2,1,3-benzoxadiazole (PDE472) is a selective inhibitor of the phosphodiesterase PDE4D isoenzyme, which is a recognised drug target for the treatment of asthma. Different synthetic routes to PDE472 were investigated, and the research synthesis was optimised to prepare a phase I batch on pilot-plant scale with the focus on the elimination or minimization of inherent process risks. An important refinement of the key Negishi aryl-aryl coupling involved preforming the arylpalladium complex, which was then added to the arylzinc intermediate. Residual palladium was removed from PDE472 via crystallization of the hemi-maleate salt, which afforded drug-substance containing 2 ppm Pd.
